7th TIL Therapies Summit

Now in its seventh year, the TIL Therapies Summit returns as the world’s leading event dedicated to advancing tumor-infiltrating lymphocyte (TIL) therapies. Taking place November 11–13, 2025, in Boston (MA), this summit unites global experts across biopharma, academia, clinical practice, and manufacturing to accelerate the development and commercialization of next-generation TIL treatments.

Following the first-ever FDA approval of a TIL therapy in the U.S., and with regulatory decisions pending in Canada and Europe, the field is at a pivotal inflection point. The 7th TIL Therapies Summit offers a timely platform to explore how optimized TIL selection, engineering, and manufacturing can unlock scalable, potent treatments for solid tumors beyond melanoma.

This year’s program is designed to tackle the most pressing challenges in TIL development, including:

Engineering TILs for improved persistence, potency, and tumor specificity
Manufacturing innovations in closed systems to speed up turnaround and reduce IL-2 dependency
Clinical trial design and patient access strategies
Biomarker discovery and potency assay development
Real-world implementation and patient/provider perspectives

With 28+ expert speakers, 80+ attendees, and 8 hours of dedicated networking, the summit fosters a collaborative environment for sharing cutting-edge science, operational insights, and lived experiences. Attendees will hear from leading voices, including:

Inge Jedema, Head of Translational Cellular Therapy, Netherlands Cancer Institute
Jingwei Sun, VP R&D, Grit Biotechnology
Madan Jagasia, CEO, Obsidian Therapeutics
Micah Benson, CSO, KSQ Therapeutics
Michael Lotze, Professor, University of Pittsburgh
Roda Amaria, Professor, MD Anderson Cancer Center

You can see who else is speaking in this year’s program: https://ter.li/i4a730

Whether you're preparing for your first clinical trial, scaling manufacturing, or navigating regulatory pathways, this summit delivers actionable insights for every stage of the TIL pipeline. Two new tracks focused on R&D and CMC ensure that both scientific and operational teams gain maximum value.

Unlike broader cell therapy events, the TIL Therapies Summit offers a focused, intimate setting where attendees can engage in meaningful dialogue, build lasting partnerships, and stay ahead of the curve in this rapidly evolving space.

If you're committed to transforming the treatment landscape for solid tumors, the 7th TIL Therapies Summit is your must-attend event for 2025.

Find out more here: https://ter.li/nfdnks